StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$3.20−0.36 (-10.11%)

Close on Nov 16, 2026Market cap $54.97MP/E –Yield –

Verrica Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Verrica Pharmaceuticals's cash was $11.20M at Jun 30, 2026. For fiscal 2025 it was $30.15M, up 201.5% from the year before. The highest annual figure on record is $70.40M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.15M+201.5%
FY2024Dec 31, 2024$10.00M-85.6%
FY2023Dec 31, 2023$69.55M+102.9%
FY2022Dec 31, 2022$34.27M-51.3%
FY2021Dec 31, 2021$70.40M+558.8%
FY2020Dec 31, 2020$10.69M+15.6%
FY2019Dec 31, 2019$9.24M-10.0%
FY2018Dec 31, 2018$10.27M+18.6%
FY2017Dec 31, 2017$8.66M+1543.8%
FY2016Dec 31, 2016$527.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$11.20M-27.3%
Q1 FY2026Mar 31, 2026$20.60M+106.0%
Q4 FY2025Dec 31, 2025$30.15M+201.5%
Q3 FY2025Sep 30, 2025$21.10M-8.1%
Q2 FY2025Jun 30, 2025$15.40M-51.8%
Q1 FY2025Mar 31, 2025$10.00M-79.6%
Q4 FY2024Dec 31, 2024$10.00M-85.6%
Q3 FY2024Sep 30, 2024$22.96M-72.8%
Q2 FY2024Jun 30, 2024$31.93M-42.1%
Q1 FY2024Mar 31, 2024$48.94M-18.4%
Q4 FY2023Dec 31, 2023$69.55M+102.9%
Q3 FY2023Sep 30, 2023$84.31M+113.4%
Q2 FY2023Jun 30, 2023$55.14M+1.4%
Q1 FY2023Mar 31, 2023$59.95M-3.1%
Q4 FY2022Dec 31, 2022$34.27M-51.3%
Q3 FY2022Sep 30, 2022$39.50M-50.3%
Q2 FY2022Jun 30, 2022$54.40M+120.2%
Q1 FY2022Mar 31, 2022$61.90M+40.4%
Q4 FY2021Dec 31, 2021$70.40M+558.8%
Q3 FY2021Sep 30, 2021$79.50M+362.3%
Q2 FY2021Jun 30, 2021$24.71M-49.5%
Q1 FY2021Mar 31, 2021$44.10M-19.1%
Q4 FY2020Dec 31, 2020$10.69M+15.6%
Q3 FY2020Sep 30, 2020$17.20M+62.2%
Q2 FY2020Jun 30, 2020$48.93M+146.5%
Q1 FY2020Mar 31, 2020$54.49M+123.1%
Q4 FY2019Dec 31, 2019$9.24M-10.0%
Q3 FY2019Sep 30, 2019$10.60M-72.3%
Q2 FY2019Jun 30, 2019$19.85M-80.8%
Q1 FY2019Mar 31, 2019$24.43M-11.1%
Q4 FY2018Dec 31, 2018$10.27M+18.6%
Q3 FY2018Sep 30, 2018$38.31M+9574.5%
Q2 FY2018Jun 30, 2018$103.15M+20285.2%
Q1 FY2018Mar 31, 2018$27.49M+5115.4%
Q4 FY2017Dec 31, 2017$8.66M–
Q3 FY2017Sep 30, 2017$396.00K–
Q2 FY2017Jun 30, 2017$506.00K–
Q4 FY2016Dec 31, 2016$527.00K–

More Verrica Pharmaceuticals figures

See a number that looks wrong?